Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Treatment of invasive fungal diseases in cancer patients - Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Ruhnke M, Cornely OA, Schmidt-Hieber M, Alakel N, Boell B, Buchheidt D, Christopeit M, Hasenkamp J, Heinz WJ, Hentrich M, Karthaus M, Koldehoff M, Maschmeyer G, Panse J, Penack O, Schleicher J, Teschner D, Ullmann AJ, Vehreschild M, von Lilienfeld-Toal M, Weissinger F, Schwartz S.

Mycoses. 2020 Mar 31. doi: 10.1111/myc.13082. [Epub ahead of print]

PMID:
32236989
2.

Evaluating Mental Load During Realistic Driving Simulations by Means of Round the Ear Electrodes.

Wascher E, Arnau S, Reiser JE, Rudinger G, Karthaus M, Rinkenauer G, Dreger F, Getzmann S.

Front Neurosci. 2019 Sep 4;13:940. doi: 10.3389/fnins.2019.00940. eCollection 2019.

3.

Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.

Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M.

Clin Colorectal Cancer. 2019 Dec;18(4):245-256.e5. doi: 10.1016/j.clcc.2019.07.009. Epub 2019 Jul 29.

4.

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.

Köhne CH, Karthaus M, Mineur L, Thaler J, Van den Eynde M, Gallego J, Koukakis R, Berkhout M, Hofheinz RD.

Drugs R D. 2019 Sep;19(3):267-275. doi: 10.1007/s40268-019-0278-8.

5.

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).

Riechelmann RP, Srimuninnimit V, Bordonaro R, Kavan P, Di Bartolomeo M, Maiello E, Cicin I, García-Alfonso P, Chau I, Fedyanin MY, Martos CF, Ter-Ovanesov M, Peeters M, Ko YJ, Yalcin S, Karthaus M, Aparicio J, Heinemann V, Picard P, Bury D, Drea E, Sobrero A.

Clin Colorectal Cancer. 2019 Sep;18(3):183-191.e3. doi: 10.1016/j.clcc.2019.05.003. Epub 2019 May 15.

6.

Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults.

Karthaus M, Schiel X, Ruhlmann CH, Celio L.

Expert Rev Clin Pharmacol. 2019 Jul;12(7):661-680. doi: 10.1080/17512433.2019.1621162. Epub 2019 Jun 13. Review.

PMID:
31194593
7.
8.

Effects of Visual and Acoustic Distraction on Driving Behavior and EEG in Young and Older Car Drivers: A Driving Simulation Study.

Karthaus M, Wascher E, Getzmann S.

Front Aging Neurosci. 2018 Dec 18;10:420. doi: 10.3389/fnagi.2018.00420. eCollection 2018.

9.

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.

Herrstedt J, Summers Y, Jordan K, von Pawel J, Jakobsen AH, Ewertz M, Chan S, Naik JD, Karthaus M, Dubey S, Davis R, Fox GM.

Support Care Cancer. 2019 Jul;27(7):2699-2705. doi: 10.1007/s00520-018-4564-8. Epub 2018 Nov 28.

PMID:
30488222
10.

Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.

Kasper S, Kisro J, Fuchs M, Müller C, Schulz-Abelius A, Karthaus M, Rafiyan MR, Stein A.

BMC Cancer. 2018 Nov 16;18(1):1124. doi: 10.1186/s12885-018-5063-5.

11.

Age-Related Differences in Pro-active Driving Behavior Revealed by EEG Measures.

Getzmann S, Arnau S, Karthaus M, Reiser JE, Wascher E.

Front Hum Neurosci. 2018 Aug 7;12:321. doi: 10.3389/fnhum.2018.00321. eCollection 2018.

12.

Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO).

Ruhnke M, Behre G, Buchheidt D, Christopeit M, Hamprecht A, Heinz W, Heussel CP, Horger M, Kurzai O, Karthaus M, Löffler J, Maschmeyer G, Penack O, Rieger C, Rickerts V, Ritter J, Schmidt-Hieber M, Schuelper N, Schwartz S, Ullmann A, Vehreschild JJ, von Lilienfeld-Toal M, Weber T, Wolf HH.

Mycoses. 2018 Nov;61(11):796-813. doi: 10.1111/myc.12838. Epub 2018 Sep 3. Review.

PMID:
30098069
13.

Evaluating Pro- and Re-Active Driving Behavior by Means of the EEG.

Wascher E, Arnau S, Gutberlet I, Karthaus M, Getzmann S.

Front Hum Neurosci. 2018 May 24;12:205. doi: 10.3389/fnhum.2018.00205. eCollection 2018.

14.

Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies.

Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M.

Ann Oncol. 2018 Jun;29 Suppl 5:v96. doi: 10.1093/annonc/mdy150.011. Epub 2020 Jan 7. No abstract available.

15.

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.

Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M.

Ann Oncol. 2018 Jul 1;29(7):1535-1540. doi: 10.1093/annonc/mdy169.

16.

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.

Peeters M, Forget F, Karthaus M, Valladares-Ayerbes M, Zaniboni A, Demonty G, Guan X, Rivera F.

ESMO Open. 2018 Feb 24;3(2):e000297. doi: 10.1136/esmoopen-2017-000297. eCollection 2018.

17.

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.

Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Bartolomeo MD, Bridgewater J, Coveler AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, Pirzkall A, Tabernero J.

Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.

18.

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.

Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G, Peeters M.

J Cancer Res Clin Oncol. 2018 Apr;144(4):795-797. doi: 10.1007/s00432-018-2591-y.

19.

Proactive vs. reactive car driving: EEG evidence for different driving strategies of older drivers.

Karthaus M, Wascher E, Getzmann S.

PLoS One. 2018 Jan 19;13(1):e0191500. doi: 10.1371/journal.pone.0191500. eCollection 2018.

20.

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.

Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G, Peeters M.

J Cancer Res Clin Oncol. 2018 Feb;144(2):321-335. doi: 10.1007/s00432-017-2534-z. Epub 2017 Oct 28. Erratum in: J Cancer Res Clin Oncol. 2018 Feb 15;:.

21.

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, Van Cutsem E, Guan X, Boedigheimer M, Ang A, Twomey B, Bach BA, Jung AS, Bardelli A.

Ann Oncol. 2018 Jan 1;29(1):119-126. doi: 10.1093/annonc/mdx504.

22.

Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, Maschmeyer G.

Ann Hematol. 2017 Nov;96(11):1775-1792. doi: 10.1007/s00277-017-3098-3. Epub 2017 Aug 30. Review.

23.

VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.

Wirapati P, Pomella V, Vandenbosch B, Kerr P, Maiello E, Jeffery Grahame M, Curca RD, Karthaus M, Bridgewater JA, Mihailov AC, Kiss I, Merino S, McKendrick Joseph J, Saridaki Z, Sagaert XJA, Tejpar S.

Ann Oncol. 2017 Jun;28 Suppl 3:iii151-iii152. doi: 10.1093/annonc/mdx302.004. No abstract available.

24.

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.

Rivera F, Karthaus M, Hecht JR, Sevilla I, Forget F, Fasola G, Canon JL, Guan X, Demonty G, Schwartzberg LS.

Int J Colorectal Dis. 2017 Aug;32(8):1179-1190. doi: 10.1007/s00384-017-2800-1. Epub 2017 Apr 19.

25.

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski CC, Staib F, Göhler T, Hebart H, Heike M, Neise M, Rudi J, Geer T, Dingeldein G, Lang C, Ehscheidt P, Flohr T, Josten KM, Karthaus M, Schmittel A, Wierecky J, Boller E, Indorf M, Wörns MA, Galle PR, Moehler M.

J Cancer Res Clin Oncol. 2017 Jun;143(6):1023-1034. doi: 10.1007/s00432-017-2344-3. Epub 2017 Feb 14.

PMID:
28197787
26.

Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study.

Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekulé A, Keller P, Kiehl M, Krause SW, Krämer C, Neumann S, Rohde H, La Rosée P, Ruhnke M, Schafhausen P, Schalk E, Schulz K, Schwartz S, Silling G, Staib P, Ullmann A, Vergoulidou M, Weber T, Cornely OA, Vehreschild MJ.

Int J Antimicrob Agents. 2017 Feb;49(2):218-223. doi: 10.1016/j.ijantimicag.2016.10.019. Epub 2016 Dec 12.

PMID:
27989379
27.

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.

Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H.

Support Care Cancer. 2017 Apr;25(4):1127-1135. doi: 10.1007/s00520-016-3502-x. Epub 2016 Nov 24.

28.

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.

Karthaus M, Hofheinz RD, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Oliner KS, Boedigheimer M, Twomey B, Zhang Y, Demonty G, Köhne CH.

Br J Cancer. 2016 Nov 8;115(10):1215-1222. doi: 10.1038/bjc.2016.343. Epub 2016 Oct 20.

29.

A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients.

Biehl LM, Huth A, Panse J, Krämer C, Hentrich M, Engelhardt M, Schäfer-Eckart K, Kofla G, Kiehl M, Wendtner CM, Karthaus M, Ullmann AJ, Hellmich M, Christ H, Vehreschild MJ.

Ann Oncol. 2016 Oct;27(10):1916-22. doi: 10.1093/annonc/mdw275. Epub 2016 Jul 25.

30.

Functional Changes and Driving Performance in Older Drivers: Assessment and Interventions.

Karthaus M, Falkenstein M.

Geriatrics (Basel). 2016 May 20;1(2). pii: E12. doi: 10.3390/geriatrics1020012. Review.

31.

Driver state examination--Treading new paths.

Wascher E, Getzmann S, Karthaus M.

Accid Anal Prev. 2016 Jun;91:157-65. doi: 10.1016/j.aap.2016.02.029. Epub 2016 Mar 14.

PMID:
26986022
32.

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ.

Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.

PMID:
26684607
33.

[Tumor dynamics: parameters for the overall benefit of therapy].

Karthaus M.

Oncol Res Treat. 2015;38(5):258-9. German. No abstract available.

PMID:
26167557
34.

Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors.

Michl M, Thurmaier J, Schubert-Fritschle G, Wiedemann M, Laubender RP, Nüssler NC, Ruppert R, Kleeff J, Schepp W, Reuter C, Löhe F, Karthaus M, Neumann J, Kirchner T, Engel J, Heinemann V.

Clin Colorectal Cancer. 2015 Dec;14(4):281-90. doi: 10.1016/j.clcc.2015.05.009. Epub 2015 Jun 6.

PMID:
26123495
35.

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.

Peeters M, Karthaus M, Rivera F, Terwey JH, Douillard JY.

Drugs. 2015 May;75(7):731-48. doi: 10.1007/s40265-015-0386-x. Review.

36.

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).

Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM.

Support Care Cancer. 2015 Oct;23(10):2917-23. doi: 10.1007/s00520-015-2657-1. Epub 2015 Feb 28.

37.

Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.

Karthaus M, Lehrnbecher T, Lipp HP, Kluge S, Buchheidt D.

Ann Hematol. 2015 Apr;94(4):547-56. doi: 10.1007/s00277-015-2333-z. Epub 2015 Feb 20. Review.

PMID:
25697592
38.

Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.

Lorusso V, Karthaus M, Aapro M.

Future Oncol. 2015;11(4):565-77. doi: 10.2217/fon.14.260. Epub 2014 Oct 31. Review.

PMID:
25360998
39.

Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Tacke D, Buchheidt D, Karthaus M, Krause SW, Maschmeyer G, Neumann S, Ostermann H, Penack O, Rieger C, Ruhnke M, Sandherr M, Schweer KE, Ullmann AJ, Cornely OA.

Ann Hematol. 2014 Sep;93(9):1449-56. doi: 10.1007/s00277-014-2108-y. Epub 2014 Jun 21. Review.

PMID:
24951122
40.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY.

J Clin Oncol. 2014 Jul 20;32(21):2240-7. doi: 10.1200/JCO.2013.53.2473. Epub 2014 Mar 31.

PMID:
24687833
41.

Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO).

Vehreschild JJ, Böhme A, Cornely OA, Kahl C, Karthaus M, Kreuzer KA, Maschmeyer G, Mousset S, Ossendorf V, Penack O, Vehreschild MJ, Bohlius J; Infectious Diseases Working Party of the Society for Haematology and Medical Oncology.

Ann Oncol. 2014 Sep;25(9):1709-18. doi: 10.1093/annonc/mdu035. Epub 2014 Mar 14.

42.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S.

Ann Oncol. 2014 Jul;25(7):1328-33. doi: 10.1093/annonc/mdu101. Epub 2014 Mar 5.

43.

Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology.

Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, Ruhnke M, Penack O, Salwender H, Wolf HH, Christopeit M, Neumann S, Maschmeyer G, Karthaus M; Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology.

Ann Oncol. 2014 May;25(5):936-47. doi: 10.1093/annonc/mdt545. Epub 2014 Jan 7.

44.

Invasive aspergillosis: new insights into disease, diagnostic and treatment.

Karthaus M, Buchheidt D.

Curr Pharm Des. 2013;19(20):3569-94. Review.

PMID:
23278538
45.

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.

Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Baños A, Köhne CH.

BMC Cancer. 2012 Sep 29;12:438. doi: 10.1186/1471-2407-12-438.

46.

Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G, Heinz W, Karthaus M, Kiehl M, Krüger W, Penack O, Reuter S, Ruhnke M, Sandherr M, Salwender HJ, Ullmann AJ, Waldschmidt DT, Wolf HH.

Ann Hematol. 2012 Aug;91(8):1161-74. doi: 10.1007/s00277-012-1456-8. Epub 2012 May 26. Review.

PMID:
22638755
47.

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.

Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M.

J Cancer Res Clin Oncol. 2012 Jan;138(1):65-72. doi: 10.1007/s00432-011-1061-6. Epub 2011 Sep 30.

PMID:
21960318
48.

Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO).

Ruhnke M, Böhme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, Enzensberger R, Hebart H, Heussel CP, Horger M, Hof H, Karthaus M, Krüger W, Maschmeyer G, Penack O, Ritter J, Schwartz S; Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology.

Ann Oncol. 2012 Apr;23(4):823-33. doi: 10.1093/annonc/mdr407. Epub 2011 Sep 23. Review.

49.

Phase II dose escalation study of caspofungin for invasive Aspergillosis.

Cornely OA, Vehreschild JJ, Vehreschild MJ, Würthwein G, Arenz D, Schwartz S, Heussel CP, Silling G, Mahne M, Franklin J, Harnischmacher U, Wilkens A, Farowski F, Karthaus M, Lehrnbecher T, Ullmann AJ, Hallek M, Groll AH.

Antimicrob Agents Chemother. 2011 Dec;55(12):5798-803. doi: 10.1128/AAC.05134-11. Epub 2011 Sep 12.

50.

Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.

Vehreschild MJ, Meissner AM, Cornely OA, Maschmeyer G, Neumann S, von Lilienfeld-Toal M, Karthaus M, Wattad M, Staib P, Hellmich M, Christ H, Vehreschild JJ.

Haematologica. 2011 Dec;96(12):1855-60. doi: 10.3324/haematol.2011.049627. Epub 2011 Aug 22.

Supplemental Content

Loading ...
Support Center